Biologics subject matter expert (SME) consulting services
Ended Purchase Order Awarded Last action
- Contract number
- 75N95022P00209
- Awardee
-
Pharmalex US Corporation UEI XFLXMFKCJQN1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $62,950
Award facts
- Opportunity
-
- Biological Therapeutics Product Development Subject Matter Expert Consulting Services to Support the Development of Therapeutic Biotechnology Products (Biologics) Solicitation · NIHNINDSCSS22000015 · Posted Oct 29, 2021
- Contract value 3% obligated
-
- $62,950.00 Current, with exercised options
- $1,884,275.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- Total Small Business
- Competition
- Competed under SAP · 6 offers Simplified Acquisition
- Pricing
- Labor Hours
- Place of performance
- Australia
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$10,525 | |
| Exercise an Option | $19,250 | |
| Exercise an Option | $19,275 | |
| Exercise an Option | $24,250 | |
| Original award | $10,700 |
About this award
This federal contract award, valued at $1,884,275.00, was issued by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency, to Pharmalex US Corporation for Biologics Subject Matter Expert (SME) Consulting Services. The contract is a total small business set-aside, with a period of performance through April 14, 2025.
The award is in support of NINDS programs such as the Blueprint Neurotherapeutics Network Biologics (BPN-Biologics), the Ultra-Rare Gene Therapy (URGenT) program, and the Helping to End Addiction Long-term Pain Therapeutics Development Program (HEAL-PTDP), which aim to develop novel biologics therapeutics for neurological disorders. The SME consultants will provide technical recommendations and advice on candidate biologics development, current Good Manufacturing Practices (cGMP) manufacturing, and Phase 1 clinical trials.
Quick answers
Who was awarded contract 75N95022P00209?
75N95022P00209 was awarded to Pharmalex US Corporation by National Institute on Drug Abuse (National Institutes of Health) on April 15, 2022.
How much is contract 75N95022P00209 worth?
The government has obligated $62,950 on 75N95022P00209. Its potential value, with all options, is $1,884,275.
Which agency awarded contract 75N95022P00209?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022P00209, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Was contract 75N95022P00209 competed?
The extent of competition for 75N95022P00209 was competed under sap. The government received 6 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award